British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently expanded on its relationship with Cannadips through a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products in Cannadips’ current California market and throughout the United States (http://cnw.fm/7V8qe). An article discussing the company reads, “Lexaria’s DehydraTECH drug-delivery platform is perfectly suited to improve the dipping experience through its effective, high-absorption technology. Cannadips uses multi-spectrum oils as base ingredients. The oils are rich in high-quality terpenes, which ensure the much-coveted entourage effect. DehydraTECH minimizes the throat irritation usually associated with some terpenes. . . . ‘Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,’ Chris Bunka, CEO of Lexaria Bioscience Corp., stated in a news release. ‘Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets.’”
To view the full article, visit http://cnw.fm/bBmR9
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor